HC Wainwright Reaffirms 'Buy' Rating for Valneva (NASDAQ:VALN)

HC Wainwright has reaffirmed a "buy" rating for Valneva (NASDAQ:VALN) in a recent report released on Friday. The investment firm set its price target at $17.00 for the company's stock. This target suggests a remarkable potential upside of approximately 146.56% based on the current trading price of Valneva.

Current Stock Performance

On Friday, Valneva's share price experienced a decline of 3.2%, dropping $0.23 to settle at $6.90. During the trading day, 4,923 shares of Valneva exchanged hands, contrasting with the company’s average trading volume of 64,338 shares. The stock has fluctuated significantly within the past year, with a fifty-two week low of $3.62 and a high of $9.50. Presently, the company holds a market capitalization of $560.29 million, along with a negative P/E ratio of -53.04 and a beta of 1.98. Valneva's stock has a 50-day moving average of $5.54 and a 200-day moving average of $5.69. Additionally, it shows a current ratio of 2.78, a quick ratio of 2.25, and a debt-to-equity ratio of 0.70.

Investments by Institutional Investors

Recently, several hedge funds have altered their positions regarding Valneva. Notably, ABC Arbitrage SA acquired a new stake in the company valued at around $84,000 in the fourth quarter. In the third quarter, AlphaCentric Advisors LLC increased its holdings in Valneva by 33.7%, now owning 118,000 shares worth $717,000 after adding 29,748 shares during that period. Furthermore, Wells Fargo & Company MN raised its stake by 14.3% in the fourth quarter, possessing 246,766 shares valued at $1,079,000 after purchasing an additional 30,859 shares. Currently, institutional investors hold 11.39% of Valneva’s stock.

About Valneva

Valneva SE is a specialized vaccine company focused on developing, manufacturing, and marketing prophylactic vaccines aimed at infectious diseases with significant unmet medical needs. The company offers several vaccines, including IXIARO, which is an inactivated vaccine for Japanese encephalitis; DUKORAL, an oral vaccine that prevents cholera and diarrhea caused by certain bacteria; IXCHIQ, a single-dose vaccine targeting the chikungunya virus; and VLA2001, an inactivated whole-virus vaccine for COVID-19.

Valneva, Investment, Rating